LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthineers Enters Agreement with HORIBA Medical

By LabMedica International staff writers
Posted on 16 Oct 2017
Print article
Siemens Healthineers (Erlangen, Germany) and HORIBA Medical (Montpellier, France) have entered into a long-term agreement to bring new and innovative hematology solutions to the market globally.

Siemens Healthineers offers products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. HORIBA Medical designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medical laboratories, clinics and university hospitals.

With HORIBA Medical as the original equipment manufacturer to complement the Siemens Healthineers portfolio, the companies will provide customers with expanded options to fulfill their hematology and multidisciplinary solution needs. Through this alliance, Siemens Healthineers aims to help laboratories transform care delivery by providing complete multidisciplinary solutions for in vitro diagnostics testing.

"With our commercial strength and global installed base of customers combined with HORIBA Medical's innovative technologies, the relationship will expand the hematology solutions available to laboratories for diagnostics testing worldwide," said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.

“Our long-term vision and continuous investments coupled with our outstanding employees have resulted in innovative hematology technology solutions. I am extremely pleased that this long-term vision has resulted in an alliance with Siemens Healthineers” said Mr. Atsushi Horiba, Chairman, President & CEO of HORIBA, Ltd.

“This alliance provides HORIBA Medical the opportunity to address the multidisciplinary requirements along with complimentary innovative technology of Siemens Healthineers. HORIBA Medical will continue offering innovative technology solutions through its Yumizen 2 brand and current distribution channels.” said Dr. Jai Hakhu, Executive Corporate Officer of HORIBA, Ltd. and President of HORIBA Medical.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more